ReviewPostepy dermatologii i alergologii2016
Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases.
Review in Postepy dermatologii i alergologii, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Pooled it
- Deep hematologic response to RD treatment in patients with multiple myeloma is associated with overexpression of IL-17R in CD138+ plasma cells.Scientific reports · 2024Article
- Role of autoreactive Tc17 cells in the pathogenesis of experimental autoimmune encephalomyelitis.Neuroprotection (Chichester, England) · 2024Article
- FAM3C/ILEI protein is elevated in psoriatic lesions and triggers psoriasiform hyperproliferation in mice.EMBO molecular medicine · 2023Article
- Neutrophils as emerging protagonists and targets in chronic inflammatory diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- Article
- IL-17 Facilitates VCAM-1 Production and Monocyte Adhesion in Osteoarthritis Synovial Fibroblasts by Suppressing miR-5701 Synthesis.International journal of molecular sciences · 2022Article
- Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action.Biomedicines · 2022Review
- Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies.Cells · 2022Review
- Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- Advances in Potential Cerebrospinal Fluid Biomarkers for Autoimmune Encephalitis: A Review.Frontiers in neurology · 2022Review
- The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Dermatology research and practice · 2022Article
- Comparison of serum concentrations of interleukins 10, 12, 17 and 35 between patients with alopecia areata and controls.Postepy dermatologii i alergologii · 2021Article
- Immunogenicity to biological drugs in psoriasis and psoriatic arthritis.Clinics (Sao Paulo, Brazil) · 2021Article
- The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis.The Journal of clinical investigation · 2020Article
- Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models.Journal of personalized medicine · 2020Article
- Evolution ofInternational journal of molecular sciences · 2020Review
- The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24.Immunity · 2020Article
- A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections.Journal of immunology (Baltimore, Md. : 1950) · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17, which contributes to development of psoriasis, opened new possibilities for further treatment modalities. Currently, one anti-IL17 biological agent is approved for the treatment - a fully human monoclonal antibody that targets IL-17A (secukinumab). Further clinical trials, including a humanized IgG4 specific for IL-17 (ixekizumab) and a fully human antibody that targets the IL-17 receptor A (brodalumab).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.